Andrzej Hellmann
Overview
Explore the profile of Andrzej Hellmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
120
Citations
3857
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Zeidan A, Boss I, Beach C, Copeland W, Thompson E, Fox B, et al.
Blood Adv
. 2021 Dec;
6(7):2207-2218.
PMID: 34972214
Azacitidine-mediated hypomethylation promotes tumor cell immune recognition but may increase the expression of inhibitory immune checkpoint molecules. We conducted the first randomized phase 2 study of azacitidine plus the immune...
22.
Zeidan A, Boss I, Beach C, Copeland W, Thompson E, Fox B, et al.
Blood Adv
. 2021 Dec;
6(7):2219-2229.
PMID: 34933333
Evidence suggests that combining immunotherapy with hypomethylating agents may enhance antitumor activity. This phase 2 study investigated the activity and safety of durvalumab, a programmed death-ligand 1 (PD-L1) inhibitor, combined...
23.
Lica J, Wieczor M, Grabe G, Heldt M, Jancz M, Misiak M, et al.
Int J Mol Sci
. 2021 Jun;
22(9).
PMID: 34066491
Poor efficiency of chemotherapeutics in the eradication of Cancer Stem Cells (CSCs) has been driving the search for more active and specific compounds. In this work, we show how cell...
24.
Szymanski M, Marek I, Hellmann A, Patel A, Bigda J, Kaska L, et al.
Wideochir Inne Tech Maloinwazyjne
. 2021 Mar;
16(1):139-144.
PMID: 33786127
Introduction: Enhanced recovery after bariatric surgery (ERABS) and other fast track protocols are currently being implemented in bariatric surgery. This approach has several benefits. However, early complications may occur and...
25.
Radich J, Hochhaus A, Masszi T, Hellmann A, Stentoft J, Gomez Casares M, et al.
Leukemia
. 2021 Mar;
35(5):1344-1355.
PMID: 33707652
The ENESTfreedom trial assessed the feasibility of treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) following frontline nilotinib treatment. Results for long-term outcomes after a...
26.
Lopatniuk P, Puchalska Z, Mital A, Mikosik A, Frackowiak J, Hellmann A, et al.
Acta Biochim Pol
. 2020 Jun;
67(2):247-257.
PMID: 32544313
B-cell Chronic Lymphocytic Leukemia (B-CLL) is the most common hematological disorder among middle-aged/elderly people in the Western countries. We have shown earlier that B-CLL cells exhibit elevated total amount and...
27.
Walewski J, Paszkiewicz-Kozik E, Michalski W, Rymkiewicz G, Szpila T, Butrym A, et al.
Br J Haematol
. 2019 Dec;
188(6):898-906.
PMID: 31792945
R-CVP (cyclophosphamide, vincristine, prednisone) and R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone + rituximab) are immunochemotherapy regimens frequently used for remission induction of indolent non-Hodgkin lymphomas (iNHLs). Rituximab maintenance (RM) significantly improves...
28.
Patel A, Hellmann A, Spychalski P, Szymanski M, Sledzinski M
Pol Arch Intern Med
. 2019 Sep;
130(1):77-78.
PMID: 31556403
No abstract available.
29.
Felberg A, Urban A, Borowska A, Stasilojc G, Taszner M, Hellmann A, et al.
Cancer Immunol Immunother
. 2019 Feb;
68(4):587-598.
PMID: 30725204
Anti-CD20 monoclonal antibodies (mAbs) rituximab and ofatumumab are potent activators of the classical complement pathway, and have been approved for the treatment of B-cell malignancies. However, complement exhaustion and overexpression...
30.
Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, et al.
Lancet Haematol
. 2019 Jan;
6(2):e67-e78.
PMID: 30642819
Background: Preclinical studies have shown synergistic antitumour effects between ibrutinib and immune-checkpoint blockade. The aim of this study was to assess the safety and activity of ibrutinib in combination with...